ReviewHNO2026
[Oncologic surgery in the context of immunotherapy, neoadjuvant treatment and HPV : Clinical, immunological and translational aspects].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck oncological surgery has long been guided by stable therapeutic principles; however, advances in tumor immunology, the emergence of neoadjuvant immunotherapy and the distinct biology of human papillomavirus (HPV)-associated carcinomas are driving a paradigm shift. This article summarizes current developments and underlying biological mechanisms, focusing on biomarkers for patient selection and response assessment. Beyond conventional radiological criteria, immunopathological parameters are gaining relevance for monitoring and evaluating treatment efficacy. Despite immuno-oncological progress, surgery remains a cornerstone but is evolving into an integrated component of multimodal treatment strategies. With the approval of perioperative pembrolizumab following the positive Keynote-689 results, neoadjuvant therapy in head and neck cancer is becoming a clinical reality, heralding a new era in head and neck oncological surgery.
Indexed as
Identifiers
41609801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.